Linked Life Data

20491280

Source:http://linkedlifedata.com/resource/pubmed/id/20491280

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
2
pubmed:dateCreated
2010-5-24
pubmed:abstractText
In a milnacipran study, ninety-six patients with major depressive disorder were treated with milnacipran, 50-100 mg/day, for 6 weeks. Severity of depression was assessed with the Montgomery and Asberg Depression Rating Scale. The purpose of this study was to determine whether norepinephrine transporter (NET) gene and serotonin transporter (5-HTT) gene polymorphisms are associated with the antidepressant response to milnacipran, a serotonin and norepinephrine reuptake inhibitor. Eighty patients completed the study. The presence of the T allele of the NET T-182C polymorphism was associated with a superior antidepressant response. In contrast, no influence of 5-HTTLPR (5-HTT linked polymorphic region) on the antidepressant response to milnacipran was detected. The results suggest that NET but not 5-HTT polymorphisms in part determine the antidepressant response to milnacipran. In a fluvoxamine study, sixty-six patients with major depressive disorder were treated with fluvoxamine, 100-200 mg/day, for 6 weeks. The authors investigated whether 5-HTTLPR was associated with the antidepressant response to fluvoxamine, a selective serotonin reuptake inhibitor. Fifty-seven patients completed the study. The short (s) allele frequency was significantly higher in the responsive individuals than in the nonresponsive ones. The results suggest that fluvoxamine is not less effective in depressive patients carrying the s allele than in those carrying the long (1) allele and it is not less effective in Japanese than in Caucasians.
pubmed:language
jpn
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Apr
pubmed:issn
1340-2544
pubmed:author
pubmed:issnType
Print
pubmed:volume
30
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
71-6
pubmed:meshHeading
pubmed-meshheading:20491280-Adult, pubmed-meshheading:20491280-Aged, pubmed-meshheading:20491280-Alleles, pubmed-meshheading:20491280-Antidepressive Agents, pubmed-meshheading:20491280-Continental Population Groups, pubmed-meshheading:20491280-Cyclopropanes, pubmed-meshheading:20491280-Depressive Disorder, Major, pubmed-meshheading:20491280-Fluvoxamine, pubmed-meshheading:20491280-Forecasting, pubmed-meshheading:20491280-Humans, pubmed-meshheading:20491280-Male, pubmed-meshheading:20491280-Middle Aged, pubmed-meshheading:20491280-Norepinephrine Plasma Membrane Transport Proteins, pubmed-meshheading:20491280-Pharmacogenetics, pubmed-meshheading:20491280-Polymorphism, Genetic, pubmed-meshheading:20491280-Promoter Regions, Genetic, pubmed-meshheading:20491280-Serotonin Plasma Membrane Transport Proteins, pubmed-meshheading:20491280-Serotonin Uptake Inhibitors, pubmed-meshheading:20491280-Young Adult
pubmed:year
2010
pubmed:articleTitle
[Prediction of antidepressant response to milnacipran and fluvoxamine using pharmacogenetical methods].
pubmed:affiliation
Department of Neuropsychiatry, St Marianna Medical University School of Medicine, 2-16-1, Sugao, Miyamae-ku, Kawasaki, 216-8511 Japan. h5higuchi@marianna-u.ac.jp
pubmed:publicationType
Journal Article, English Abstract, Review